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Background: Resistance to chemotherapy represents a major obstacle in correcting colorectal carcinomas (CRC).
Inspite of recent advances in the treatment of metastatic disease, the prognosis of the patients remains poor. RLX, a
vasicinone analogue has been reported to possess potent bronchodilator, anti-asthmatic and anti-inflammatory
properties. However, its anti-cancer activity is unknown.
Results: Here, we report for the first time that RLX has anti-cancer property against panel of human cancer cell lines
and most potent activity was found against HCT-116 cells with IC50 value of 12 μM and have further investigated
the involvement of NFκB and caspase-3 in RLX action in CRC apoptosis. Following RLX and BEZ-235 treatment in
HCT-116, we observed significant down-regulation of NFκB (1 to 0.1 fold) and up-regulation of caspase-3 (1 to 2
fold) protein expressions. Additionally, morphological studies revealed membrane blebbing, cell shrinkage, chromatin
condensation and finally apoptosis in HCT-116 cells.
Conclusions: Overall, these findings indicate that RLX is a potent small molecule which triggers apoptosis, and
promising potential candidate to be a chemotherapeutic agent.
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According to Global cancer statistics, throughout world,
cases of colorectal carcinoma (CRC) switched to 1.2 mil-
lion with more than 600000 deaths per year [1]. In females,
CRC is the second leading commonly diagnosed and third
highly mortal cancer whereas in case of males, it is the
third most commonly diagnosed and fourth most common
cause of mortality. Promotion from normal colonic epithe-
lial cells into a colorectal carcinoma is a multifactorial
process. There are many factors like cell proliferation,
inflammation, migration and angiogenesis which play
an important role in CRC development and progression
[2]. Conventional combination chemotherapy regimens
involving FOLFOX (5-FU with leucovorin and oxaliplatin),
FOLFORI (5-FU with leucovorin and irinotecan), IFL
(Irinotecan, 5-FU, leucovorin) and XELOX (Capecita-
bine and oxaliplatin) for the treatment of colorectal* Correspondence: ahdar@iiim.ac.in
1Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine,
Jammu 180001, India
Full list of author information is available at the end of the article
© 2014 Qazi et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cancer [3] have limited efficacy and are associated with
significant toxicity.
Colorectal cancer represents a life-threatening compli-
cation of inflammatory bowel diseases where NFκB is a
natural suspect in providing a mechanistic link between
inflammation and carcinogenesis. Presently, it is believed
that increasing knowledge on genetic control of cellular
proliferation, migration and modulation of key proteins
like NFκB that are aberrant in colorectal cancer have the
potential to provide an effective and improved approach
for its management [4]. The molecular mechanisms
underlying this process have only recently started to be
clarified with biochemical and genetic studies [5]. NFκB
is a key inflammatory mediator involved in initiation,
progression and metastasis of CRC [6]. A variety of car-
cinogens and tumor promoters have shown to activate
NFκB. Constitutive expression of NFκB is frequently
found in tumor cells and is constitutively activated in a
number of human cancers via PI3K signaling [7]. Fur-
thermore, NFκB activation is regulated by caspase-3
which cleaves IκBα, generating a cleavage fragment that
potentially acts as a constitutive inhibitor of NFκB [8].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported to be implicated in the HCT-116 apoptotic cell
death [9]. In vitro treatment of HCT-116 cell lines with
NVP-BEZ235, a dual pan-class I PI3K and mTOR kinase
inhibitor in clinical trials has shown decrease in cell via-
bility and ex-vivo analysis of tumors demonstrated a 56%
decreased proliferation in CRC [10].
Adhatoda vasica Nees (family Acanthaceae), commonly
known as Vasaka or Arusha is a well known herb in indi-
genous system of medicine for its beneficial effects. Vasici-
none obtained from leaves of Adhatoda vasica Nees has
been reported for moderate degree of bronchodilator and
anti-cancer activity. In previous study, it has been shown
that RLX, a vasicinone analogue has varied medicinal prop-
erties [11,12]. Here, we report for the first time that RLX
has potent anti-cancer property against colon cancer HCT-Table 1 Growth inhibitory effect of vasicinone analogues, BEZ
lines
Tissue type Leukemia Prostate B
Cell type THP-1 PC-3 T47D
S. No Structure Conc (μM)
1 50 53 ± 2 30 ± 3 66 ± 2
30 52 ± 3 29 ± 2 55 ± 1
20 44 ± 4 21 ± 1 42 ± 0
10 32 ± 2 12 ± 4 12 ± 5
5 4 ± 1 5 ± 3 6 ± 2
2 50 42 ± 1 30 ± 2 49 ± 3
30 40 ± 2 23 ± 3 42 ± 2
20 33 ± 2 11 ± 2 35 ± 3
10 20 ± 1 7 ± 2 30 ± 3
5 8 ± 2 1 ± 3 10 ± 1
3 50 45 ± 1 37 ± 3 30 ± 3
30 42 ± 2 29 ± 1 22 ± 2
20 6 ± 2 10 ± 2 21 ± 1
10 4 ± 1 9 ± 1 4 ± 1
5 3 ± 3 8 ± 2 1 ± 3
4 50 30 ± 3 40 ± 1 20 ± 2
30 22 ± 1 27 ± 2 10 ± 1
20 21 ± 3 20 ± 1 8 ± 1
10 4 ± 1 18 ± 1 7 ± 1
5 2 ± 2 11 ± 3 2 ± 1
5 BEZ-235 10nM - - 50 ± 2
6 5-Flurouracil 20 μM - - -
Bold values represent active concentration for particular cell lines.116 cells. Under the tested experimental conditions, we
established a differential anti-cancer effect of RLX in com-
parison with BEZ-235. The results demonstrated that RLX
inhibits cell proliferation, decreases NFκB and increases
caspase-3 expression, suppresses cell migration, causes cell
membrane blebbing followed by nuclear condensation of
colon cancer cell and culminate apoptosis in HCT-116
cells. These findings revealed the importance of RLX as an
anti-cancer agent in treatment of colon carcinoma.
Results
In vitro screening of vasicinone analogues and BEZ-235
improves growth inhibitory effect in various human
cancer cell Line
We evaluated inhibitory efficacy in-vitro MTT viability
assay against panel of cancer cell lines and relative IC50-235 and 5-Flurouracil against panel of human cancer cell
reast Pancreas Colon Epithelial (Normal)
MCF-7 MIAPaca 2 HCT-116 Caco-2 fR-2
% Growth inhibition
68 ± 2 53 ± 3 96 ± 1 30 ± 3 20 ± 2
54 ± 1 40 ± 5 82 ± 1 26 ± 4 14 ± 1
42 ± 2 31 ± 4 79 ± 2 20 ± 5 12 ± 2
32 ± 1 14 ± 3 37 ± 2 10 ± 2 8 ± 1
11 ± 1 5 ± 2 4 ± 1 5 ± 1 3 ± 2
33 ± 3 47 ± 3 43 ± 3 10 ± 3 10 ± 2
20 ± 3 41 ± 2 27 ± 1 3 ± 2 6 ± 1
11 ± 3 39 ± 3 20 ± 1 2 ± 2 4 ± 2
1 ± 1 18 ± 2 18 ± 2 1 ± 3 1 ± 1
1 ± 1 9 ± 1 11 ± 3 1 ± 3 1 ± 2
5 ± 1 44 ± 3 29 ± 1 10 ± 3 12 ± 1
2 ± 1 30 ± 2 29 ± 3 8 ± 2 10 ± 1
2 ± 2 15 ± 1 21 ± 2 3 ± 3 6 ± 2
1 ± 1 11 ± 3 21 ± 2 1 ± 1 2 ± 1
1 ± 1 10 ± 2 5 ± 3 1 ± 2 3 ± 1
49 ± 2 12 ± 1 30 ± 2 10 ± 1 20 ± 1
40 ± 1 10 ± 2 23 ± 1 10 ± 2 16 ± 2
19 ± 3 6 ± 1 11 ± 3 7 ± 1 14 ± 1
10 ± 1 2 ± 1 7 ± 3 5 ± 1 11 ± 2
4 ± 2 1 ± 3 1 ± 3 2 ± 3 10 ± 1
- 53 ± 4 51 ± 1 - 26 ± 1
- - 62 ± 1 - 70 ± 2
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dicated concentrations (5, 10, 20, 30 and 50 μM), BEZ-
235 (10 nM) and 5-Flurouracil (20 μM) (Table 1) against
Leukemia (THP-1), Prostate (PC-3), Breast (MCF-7,
T47D), Pancreatic (MIAPaca 2), Colon (HCT-116, Caco-2)
cancer cell lines and normal epithelial cells (fR-2) for 48 h.
Among molecules tested, RLX (Figure 1A) showed con-
centration dependent inhibitory effect on cell proliferation
against THP-1, T47D, MIAPaca 2, MCF-7 and HCT-116
cancer cell lines and most potent inhibition against
HCT-116 whereas no significant effect on cell viability
was observed in cells treated with other analogues at
same concentrations. The MTT assay result revealed
that HCT-116 cells treated with RLX induced growth






















Figure 1 Effect of RLX on cell proliferation. (A) Chemical structure of RL
(B) Percentage growth inhibition of RLX (5 μM, 10 μM, 20 μM, 30 μM and 5
epithelial cell line. As depicted in Figure, RLX showed concentration depen
30 μM and 50 μM against HCT-116 cells.concentration of 50, 30 and 20 μM (Figure 1B). How-
ever, BEZ-235 (Positive control) at 10nM showed only
50%, 53% and 51% growth inhibition against T47D,
MIAPaca-2 and HCT-116 whereas 5-FU (Positive con-
trol) a known anticancer agent against colon cancer,
showed 56% growth inhibition against HCT-116 with
cytotoxicity against normal epithelial cells (fR-2). Fur-
thermore, IC50 value of RLX was calculated against
panel of cell lines which was found least against HCT-
116 cells (12 μM) (Table 2). Moreover, RLX showed
growth inhibition of 23%, 14%, 12%, 8% and 3% at 50,
30, 20, 10 and 5 μM against fR-2 (Normal epithelial),
indicated that it requires six to eight time’s higher con-
centration of RLX to induce 50% cell death in normal









X (7, 8, 9, 10-Tetrahydroazepino [2, 1-b] quinazolin-12(6H)-one).
0 μM) against panel of human cancer cell lines including normal
dent growth inhibition and potent effect were shown at 20 μM,
Table 2 Calculated IC50 values of RLX against human
cancer cells and normal epithelial cells





Pancreas MIAPaca 2 25
Colon HCT-116 12
Colon Caco-2 >50
Epithelial (Normal) fR-2 >>50
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116 as reflected by its relative IC50 values and no cyto-
toxicity against fR-2 cells.
Effect of RLX treatment on NFκB and caspase-3 protein
expression in HCT-116 cell line
We next examined the effect of RLX on NFκB and
caspase-3 protein expression levels by western blotting.
Following RLX (0, 10, 20 and 30 μM) treatment for 48 h,
western blot analysis revealed that RLX decreased 1 to 0.1
fold expression level of NFκB (p65) (Figure 2A) andCaspase-3
65 KDa NFκB (p65
42 KDa
β actin
BEZ-235(10nM)     +             -            -             -             -         





BEZ-235(10nM)   +           -               -            -             -        
RLX (µM)             -           0             10          20          30    
β actin
Figure 2 Protein expression in presence of RLX. (A and C) Western blo
expression at 10, 20 and 30 μM of RLX and BEZ-235(10 nM) for 48 h incuba
and increase in caspase-3 expression at 30 μM with respect to untreated aincreased 1 to 2 fold caspase-3 expression level (Figure 2C).
However, significant effect on expression of NFκB protein
was observed at 20 and 30 μM (Figure 2B) and caspase-3
at 10, 20 and 30 μM (Figure 2D) RLX concentration as
compared to untreated and BEZ-235(10nM) (Positive
control) thereby suggesting NFκB down-regulation and
caspase-3 up-regulation by RLX action.
Exposure of RLX inhibits cell migration of HCT-116 cell
monolayers
Cell migration experiment was performed to confirm
the inhibitory effect of RLX in HCT-116 cells. As shown
in Figure 3A, RLX treatment at 10, 20 and 30 μM
showed HCT-116 cell migration inhibition when com-
pared to untreated (0 μM) and BEZ-235 (10 nM). How-
ever, at increased concentrations of RLX (20 and 30 μM),
HCT-116 cells showed significant cell migration inhibition
in a concentration dependent manner as compared to un-
treated control (Figure 3B).
RLX treatment culminate microvilli loss in HCT-116 cells
As exhibited in Figure 4A, untreated cells were having
intact microvilli all over the surface. However, RLX treat-
ment at 10, 20 and 30 μM resulted in blebbing of the
































































t analysis revealed decrease in NFκB (p65) and increase in caspase-3
tion. (B and D) RLX treatment led significant decrease in NFκB (p65)
nd BEZ-235(10 nM). ***p ≤ 0.001, **p ≤ 0.01.



























Figure 3 Cell migration in HCT-116. (A) Wound healing assay of HCT-116 stable cell lines. Cells were seeded in 6 well plate and after overnight
incubation confluent monolayer cells were scraped with sterile 200 μl pipette tip and allowed to migrate for 48 h in presence of different
concentrations of RLX. The wounded areas were photographed at 48 h. Wound areas were measured by Image J software. (B) RLX showed
concentration dependent cell migration inhibition in HCT-116 monolayers. Significant inhibition on cell migration was found at 30 μM concentration
of RLX as compared to untreated and BEZ-235 control. Results are presented as mean ± standard deviation. ***p≤ 0.001, **p≤ 0.01.
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of size and blebbing of the plasma membrane and apop-
totic body formation were observed at 30 μM concentra-
tion of RLX when compared with untreated and BEZ-235.
Overall, SEM data clearly demonstrated typical early
apoptotic phenomena and loss of microvilli as compared
to untreated control.
Nuclear condensation in RLX treated HCT-116 cells
We next examined the morphological insights caused
by RLX in HCT-116 cells using diamidine phenyl indole-
dihrdrochloride (DAPI) staining. Uniformly spherical
HCT-116 cell with normal morphology was observed in
untreated cultures, whereas chromatin condensation and
chromosomal DNA cleavage were observed when HCT-
116 cells were treated with RLX (10, 20, 30 μM) and
BEZ-235 (10 nM). As shown in Figure 4B, with increase
in concentration (10, 20, 30 μM) of RLX there is increasein nuclear condensation and formation of apoptotic vesi-
cles. However, prominent effect was seen at a concentra-
tion of 20 and 30 μM treated cultures. Overall these
results suggested the ability of RLX to induce apoptotic
morphology in HCT-116 cells.
Discussions
In current study, an interesting correlation was revealed
for the first time between various regulatory and pheno-
typic events of RLX with apoptosis. We first evaluated
the growth inhibitory and cytotoxic effect of vasicinone
analogues including RLX against panel of human cancer
cell lines in vitro which includes Leukemia (THP-1),
Prostate (PC-3), Breast (MCF-7, T47D), Pancreatic
(MIAPaca 2), Colon (HCT-116, Caco-2) and normal epi-
thelial cells (fR-2). Notably, we found for the first time
that RLX inhibited cell growth and more importantly
showed concentration dependent inhibition against panel
A 









Figure 4 Microscopic studies in presence of RLX. (A) Scanning electron microscopy in HCT-116 cells. The untreated control cells (0 μM)
showed rough surface and microvilli. The treatment of RLX for 24 h caused reduction in cell size, smoothening of cell surface, blebbing of the
plasma membrane and loss of microvilli. (B) Fluorescence microscopy in HCT-116 cells. HCT-116 cells were treated with different concentration of
RLX for 48 h and stained with DAPI followed by analysis for nuclear condensation. Data are representative of one of the three
independent experiments.
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growth inhibition following RLX treatment was observed
in human colon cancer cell line i.e. HCT-116. Keeping this
in view, we further evaluated IC50 value of RLX against
THP-1, PC-3, MCF, T47D, MIAPaca-2, HCT-116, Caco-2
and fR-2 cell lines by MTT assay, which was found mini-
mum in HCT-116 cells. Overall, these results depicted
that RLX showed significant effect against HCT-116 and
least effect on Caco-2 colon cancer cell proliferation as
reflected by relative IC50 value. Since the NFκB pathway is
important for cell survival, proliferation, cell cycle pro-
gression and migration which therefore affects regulationof proliferative, anti-apoptotic, pro-apoptotic and cell
cycle regulatory molecules and thus results in cell survival,
proliferation, progression and migration of numerous can-
cers [13]. NFκB promotes cell survival via the induction
of proteins that inhibits the components of apoptotic
machinery in normal as well as cancerous cells [14]. To
evaluate the mechanism by which effect of RLX occurred,
we further examined the effect on NFκB protein expres-
sion. The most abundant form of NFκB consists of a p50
subunit and a p65 subunit. In its inactive form, NFκB is
located in the cytoplasm however, upon activation by vari-
ous stimuli, it translocates to the nucleus, where it may
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Notably, our study demonstrated that exposure to RLX re-
sulted in remarkable down-regulation in expression of
NFκB (p65). Furthermore, caspases play a pivotal role in
the mechanism of apoptosis as they are both the initiators
and executioners. Among caspases, caspase-3 is a fre-
quently activated death protease, which catalyzes the spe-
cific cleavage of many key cellular proteins resulting in
apoptosis [16]. Importantly, caspase-3 is crucial for apop-
totic chromatin condensation and DNA fragmentation in
all cell types. Here, we show that RLX mediates caspase-3
up-regulation in HCT-116 cells. Taken together, these data
indicated that NFκB and caspase-3 play a pivotal role in
mediating RLX induced apoptosis in HCT-116 cells. Cell
migration plays a critical role in tumor cell invasion and
metastasis [17]. Cell migration and invasion represents an
important property for chemotherapeutic agent other than
having potential to cause specific cancer cell death. Mole-
cules involved in cancer cell migration could be potential
target for anti-metastasis therapy. We summarize how
colon cancer cell migrate using RLX which is tested by
measuring the gap between control and treatment groups.
Although RLX was found to actively inhibit colon cancer
cell migration. Notably, apoptosis is morphologically char-
acterized by chromatin condensation, inter-nucleosome
fragments, cell shrinkage, membrane blebbing and forma-
tion of apoptotic bodies without disruption of plasma
membrane [18]. In view of promising potential of RLX as
an apoptotic agent, we further performed scanning elec-
tron microscopy (SEM) to assess early apoptotic morpho-
logical changes in HCT-116 cells. Data depicted a loss of
microvilli on the surface of treated colon malignant cells
and therefore revealed smoothening of cell surface which
altogether validates formation of typical apoptotic feature
on RLX treatment. This was supported by fluorescence
microscopy using DAPI with subsequent features of cell
shrinkage, membrane blebbing, chromatin condensation
and nuclear fragmentation in contrast to the control cells,
which retained their polygonal structure.
Conclusions
We report for the first time that RLX has target based
anticancer activity. A very important property for a can-
didate anti-cancer drug is the ability to induce tumor
cell apoptosis [19] and RLX exhibits this important char-
acteristic feature. These findings should be useful for de-
velopment of molecule(s) targeted against various cancer
signaling pathways.
Methods
Chemicals and source of antibodies and kits
Growth medium (MEM/RPMI), fetal calf serum, trypsin,
penicillin, streptomycin, DMSO, proteinase K, RIPA Buffer,
bisacrylamide, SDS, MTT dye, acrylamide, ammoniumpersulfate (APS), N, N, N’, N’ tetramethylethylenediamine
(TEMED), 2-mercaptoethanol, DAPI, Tris base. All the
above mentioned chemicals were obtained from Sigma.
Chemiluminescent western blotting kit (Millipore), Quanti
Pro BCA assay kit, 96 and 6 well plate (Iwaki), triton X
(Hi-Media), EDTA (Hi-Media), ELISA plate reader
(Bio-Rad). NFκB (p65), caspase-3 antibodies were pur-
chased from Millipore Pvt Ltd.
Synthesis and structure of RLX
Synthesis of RLX been reported previously [11]. Chemical
structure of RLX is shown in Figure 1A.
Cell lines, growth medium and treatment conditions
Human cancer cell lines; Leukemia (THP-1), Prostate
(PC-3), Colon (HCT-116, Caco-2), Breast (T47D, MCF-7)
Pancreatic (MIAPaca 2) and Normal epithelial (fR-2)
were procured from European Collection of cell culture
(ECACC), UK. Cells were grown in Minimum Essential
Medium (MEM) and Roswell Park Memorial Institute
medium (RPMI) supplemented with 10% FCS and 1%
penicillin. Penicillin was dissolved in PBS and sterilized
by filtering through 0.2 μm filter in laminar air flow hood.
Cells were cultured in CO2 incubator (New Brunswick,
Galaxy 170R, eppendroff) with an internal atmosphere of
95% air and 5% CO2 gas and the cell lines were main-
tained at 37°C. The media was stored at low temperature
(2-8°C) and the medium for cryopreservation contained
20% FCS and 10% DMSO in growth medium.
Cell viability assay
The MTT assay was used to assess the effect of the mol-
ecules on cell viability. In each well of a 96-well plate,
cells with different densities were grown in 100 μL of
medium. After 24 h, RLX was added to achieve a final
concentration of 50, 30, 20, 10, 5 μM, BEZ-235 (10 nM)
and 5-Flurouracil (20 μM) (Positive controls) respect-
ively. 4 h prior to the completion of 48 h treatment of
RLX and BEZ-235, 20 μL of 2.5 mg/mL of MTT solution
in PBS was added to each well. After 48 h, supernatant was
removed and formazan crystals were dissolved in 150 μL
of DMSO. Absorbance was then measured at 570 nm
using an absorbance plate reader (Bio-Rad Microplate
Reader). Data was expressed as percentage of the viable
cells in treated relative to untreated conditions. The experi-
ments were repeated thrice and carried in triplicates [20].
Preparation of whole cell lysates and western blot
analysis
HCT-116 (2 × 106 cells/ml/well) cells were treated with
RLX at 0 (untreated), 10, 20, 30 μM and BEZ-235 (10 nM)
(Positive control) for 48 h. After that cells were trypsinized
and suspended in cold RIPA buffer (150 mM NaCl, 1.0%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
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vortexed and then centrifuged at 14,000 g for 15 min.
Supernatant thus obtained was whole cell lysate which
was stored at -20°C for future use. Protein content was
measured using BSA (1 mg/ml) and samples with un-
known concentrations were plotted in a linear range of 0.5
to 30 μg/ml of the protein concentration and absorbance
measured at 562 nm. The above protein lysates were sub-
jected to discontinuous SDS-PAGE at 100 V and electro
transferred to polyvinylidene difluoride (PVDF) mem-
brane (Millipore) for 2 h at 120 V at 4°C. The membrane
was blocked with 3% skimmed milk in PBS for 1 h.
After blocking, the membrane was probed with specific
primary antibody for overnight at 4°C followed by 3
times washing with TBST for 5 min each. A dilution of
secondary antibody (mouse and rabbit) conjugate was
added for 1 h of incubation and signals were detected
using Millipore Chemiluminescent western blotting kit
and analyzed using X-ray film [20].
Cell migration Assay
HCT-116 cell monolayer (90% confluent) was allowed to
become quiescent in medium with 0.1% dialyzed fetal
bovine serum for 24 h. Further, cells were scraped to
make a straight line wound and treated with RLX and
BEZ-235 (Positive control) for 48 h. Photographs were
taken through an inverted microscope (×40 magnifica-
tion) at 48 h and lengths of wound were determined by
Image J (version 1.46) software [21].
Cell surface examination with scanned electron
microscopy
HCT-116 (0.5 × 105 cells/ml) were treated with RLX at
0 (untreated), 10, 20, 30 μM and BEZ-235(10nM) (Posi-
tive control) concentration for 24 h. Following PBS
wash, fixation of cells was done with 2.5% glutaralde-
hyde in 0.1 M cacodylate buffer for 1 h at 4°C and post
fixed with 1% OsO4 in the same buffer for 1 h at room
temperature. Dehydration was done with ascending
grades of acetone following critical point drying using
liquid CO2. Gold coating (thickness 20 nm) was done
using sputter coater and viewed under electron micro-
scope (JEOL JEM -100CXII) with ASID at 40KV [20].
Apoptotic characterization using fluorescence microscopy
HCT-116 (5 × 105 cells/ml/well) cells were treated with
RLX 0 (untreated), 10, 20, 30 μM and BEZ-235 (10 nM)
(Positive control) concentrations. After 48 h of incuba-
tion, cells were centrifuged at 3000 rpm for 5 min. Re-
suspended pellet was dissolved in PBS. The air dried
smears were fixed in methanol at -20°C, stained with
DAPI (1 μg/ml) and kept at 37°C for 20 minutes. Follow-
ing PBS wash, mounting was done with glycerol: PBS
(90:10) on coverslip and prepared slides were observedunder fluorescence microscope (Olympus) using UV fil-
ter at 40× magnification [20].
Statistical evaluation
The results of three independent experiments were
expressed as the mean ± SD. Statistical evaluation was per-
formed using an un-paired t-test. ***p ≤ 0.001, **p ≤ 0.01,
*p ≤ 0.05.
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